Carl Zeiss Meditec Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Maximilian Foerst
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 5.5yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Carl Zeiss Meditec AG's (ETR:AFX) Share Price Matching Investor Opinion
Aug 29
Carl Zeiss Meditec AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 10Carl Zeiss Meditec (ETR:AFX) Could Be Struggling To Allocate Capital
Jul 01Why Carl Zeiss Meditec's (ETR:AFX) Shaky Earnings Are Just The Beginning Of Its Problems
May 19Is It Time To Consider Buying Carl Zeiss Meditec AG (ETR:AFX)?
May 16Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 39%?
Apr 28Carl Zeiss Meditec (ETR:AFX) Will Pay A Smaller Dividend Than Last Year
Mar 23Shareholders Will Probably Be Cautious Of Increasing Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation At The Moment
Mar 20After Leaping 25% Carl Zeiss Meditec AG (ETR:AFX) Shares Are Not Flying Under The Radar
Mar 15These 4 Measures Indicate That Carl Zeiss Meditec (ETR:AFX) Is Using Debt Extensively
Mar 03Carl Zeiss Meditec (ETR:AFX) Might Be Having Difficulty Using Its Capital Effectively
Feb 10More Unpleasant Surprises Could Be In Store For Carl Zeiss Meditec AG's (ETR:AFX) Shares After Tumbling 26%
Jan 10Is Carl Zeiss Meditec AG (ETR:AFX) Potentially Undervalued?
Dec 28
AI-Powered Innovations Like KINEVO 900 S And VISUMAX 800 Set To Drive Revenue Growth
New product pipeline and integration of DORC expected to drive revenue and enhance net margins with innovative AI medical solutions.Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Dec 04Carl Zeiss Meditec AG's (ETR:AFX) Share Price Could Signal Some Risk
Nov 19Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital
Sep 19Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Sep 06Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?
Aug 23At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?
Aug 09Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Jul 11Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled
Jun 10Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing
May 26Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 11Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
May 09Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?
Mar 24Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Mar 11Slowing Rates Of Return At Carl Zeiss Meditec (ETR:AFX) Leave Little Room For Excitement
Feb 12Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jan 29What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?
Dec 08Carl Zeiss Meditec (ETR:AFX) Is Experiencing Growth In Returns On Capital
Nov 08Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 37% Above Its Share Price
Oct 24Is Carl Zeiss Meditec (ETR:AFX) A Risky Investment?
Sep 24Should You Investigate Carl Zeiss Meditec AG (ETR:AFX) At €85.72?
Sep 08Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jul 24We Like These Underlying Return On Capital Trends At Carl Zeiss Meditec (ETR:AFX)
Jun 19Should You Think About Buying Carl Zeiss Meditec AG (ETR:AFX) Now?
Jun 06Is Now The Time To Put Carl Zeiss Meditec (ETR:AFX) On Your Watchlist?
May 22Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 24% Below Its Share Price
Apr 19Carl Zeiss Meditec (ETR:AFX) Has A Pretty Healthy Balance Sheet
Feb 26Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 10Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Jan 28CEO
Maximilian Foerst (56 yo)
less than a year
Tenure
Mr. Maximilian Foerst is President, CEO & Member of Management Board of Carl Zeiss Meditec AG from June 1, 2025. He serves as Chairman of Management Board at Carl Zeiss Meditec AG since 2025. He has had a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & Member of the Management Board | 7yrs | €784.50k | no data | |
| Head of Global Regulatory & Clinical Affairs | 2.8yrs | €22.50k | no data | |
| Chairman of the Management Board | less than a year | no data | no data | |
| Chief Operating Officer | no data | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Chief Human Resources Officer | no data | no data | no data | |
| Chief Medical Officer for Global Ophthalmic Devices | 9yrs | no data | no data | |
| Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec | 5.6yrs | no data | no data | |
| President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit | 5.4yrs | no data | no data | |
| Head of the Microsurgery Strategic Business Unit - ZEISS Medical Technology | no data | no data | no data |
5.5yrs
Average Tenure
58yo
Average Age
Experienced Management: AFX's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Head of Global Regulatory & Clinical Affairs | 2.6yrs | €22.50k | no data | |
| Honorary Chairman of the Supervisory Board | 4.4yrs | €43.10k | no data | |
| Shareholder Representative Member of Supervisory Board | 5.3yrs | €36.00k | no data | |
| Shareholder Representative Member of the Supervisory Board | 4.4yrs | €55.00k | no data | |
| Employee Representative Member of the Supervisory Board | 2.6yrs | €24.50k | no data | |
| Shareholder Representative Member of the Supervisory Board | 7.5yrs | €43.10k | no data | |
| Employee Representative Deputy Chairman of Supervisory Board | 6yrs | €55.60k | no data | |
| Employee Representative Member of Supervisory Board | 5.6yrs | €38.60k | no data | |
| Shareholder Representative Member of Supervisory Board | 4.4yrs | no data | no data | |
| Employee Representative Member of the Supervisory Board | 3.6yrs | €36.00k | no data | |
| Employee Representative Member of the Supervisory Board | 2.6yrs | €19.90k | no data | |
| Chairman of Supervisory Board | less than a year | no data | no data |
4.4yrs
Average Tenure
54yo
Average Age
Experienced Board: AFX's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 02:44 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Carl Zeiss Meditec AG is covered by 34 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathon Unwin | Barclays |
| Scott Bardo | Berenberg |
| Samuel England | Berenberg |